ENZYME REPLACEMENT THERAPY FOR PATIENTS
WITH FABRY DISEASE
This site is intended for use by residents of the United Kingdom only.
Please enter the site most relevant to you.
The information on this website is intended only to provide information about Replagal (agalsidase alfa). This information should not be used in place of advice from your GP or other healthcare professional.
The Replagal website is intended for residents of the United Kingdom only. This website has been produced by Shire Human Genetic Therapies, a business unit of Shire plc. The website has been developed in accordance with industry and legal standards to provide information for the general public, patients and their families, and also healthcare professionals about Replagal. Shire Human Genetic Therapies makes every reasonable effort to include accurate and current information. However, the information provided on the website is not exhaustive. References for published sources of information cited on the Replagal website have been provided on the relevant pages.
Sponsored by Shire Human Genetic Therapies, a business unit of Shire plc. Registered in Jersey 99854. Registered Office: 22 Grenville Street, St Helier, Jersey JE4 8PX.
UK Offices: Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP.
Email: medinfouk@shire.com